Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Baichuan Antihypertensive Capsule is a traditional Chinese medicine (TCM) formulation developed by Xi'an Jiaotong University for the treatment of primary hypertension. It is specifically indicated for patients exhibiting the TCM pattern of blood stasis and qi stagnation. The drug is a multi-component herbal extract designed to promote blood circulation and regulate qi flow, which are traditional therapeutic strategies for managing hypertension in Chinese medicine. It has been evaluated in randomized, double-blind, placebo-controlled Phase 2 clinical trials in China to assess its safety and efficacy in lowering blood pressure in patients with grade I–II primary hypertension.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Baichuan Antihypertensive Capsule.